21.36 USD
+0.24
1.14%
Updated Aug 26, 12:37 PM EDT
1 day
1.14%
5 days
3.44%
1 month
2.99%
3 months
18.67%
6 months
3.04%
Year to date
11.77%
1 year
15.96%
5 years
-8.01%
10 years
-23.58%
 

About: Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.

Employees: 12,300

0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 8 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,186% more call options, than puts

Call options by funds: $6.77M | Put options by funds: $526K

100% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]

16% more capital invested

Capital invested by funds: $3.33B [Q1] → $3.86B (+$529M) [Q2]

4.5% more ownership

Funds ownership: 111.99% [Q1] → 116.49% (+4.5%) [Q2]

7% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 46

3% less funds holding

Funds holding: 286 [Q1] → 278 (-8) [Q2]

21% less repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 116

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$17
20%
downside
Avg. target
$21
3%
downside
High target
$25
17%
upside

8 analyst ratings

positive
38%
neutral
50%
negative
13%
Mizuho
Steven Valiquette
16%downside
$18
Underperform
Maintained
1 Aug 2025
Stifel
Jonathan Bock
17%upside
$25
Buy
Maintained
1 Aug 2025
Morgan Stanley
Erin Wright
20%downside
$17
Equal-Weight
Maintained
1 Aug 2025
Wells Fargo
Vik Chopra
11%downside
$19
Equal-Weight
Maintained
1 Aug 2025
Piper Sandler
Jason Bednar
11%downside
$19
Neutral
Maintained
1 Aug 2025

Financial journalist opinion

Based on 15 articles about NVST published over the past 30 days

Neutral
Zacks Investment Research
23 hours ago
NVST or ABT: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
NVST or ABT: Which Is the Better Value Stock Right Now?
Negative
Zacks Investment Research
1 week ago
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.
4 Medical Product Stocks to Watch From a Challenging Industry
Positive
Zacks Investment Research
1 week ago
4 Stocks Trading Near 52-Week High With More Upside Potential
Stocks like FHI, NVST, COMM and FLS are seeing price strength and have a high chance of carrying the momentum forward.
4 Stocks Trading Near 52-Week High With More Upside Potential
Positive
Zacks Investment Research
1 week ago
Earnings Estimates Moving Higher for Envista (NVST): Time to Buy?
Envista (NVST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Earnings Estimates Moving Higher for Envista (NVST): Time to Buy?
Positive
Zacks Investment Research
2 weeks ago
4 GARP Stocks With Solid PEG Scores for Strong Portfolio Gains
Four GARP picks with low PEG ratios and strong growth potential include Kontoor Brands, Envista, Western Digital and LATAM Airlines.
4 GARP Stocks With Solid PEG Scores for Strong Portfolio Gains
Positive
Zacks Investment Research
2 weeks ago
Why Envista (NVST) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Envista (NVST) is a Top Momentum Stock for the Long-Term
Neutral
Zacks Investment Research
2 weeks ago
NVST vs. ABT: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
NVST vs. ABT: Which Stock Is the Better Value Option?
Positive
The Motley Fool
2 weeks ago
Envista Q2 Revenue Jumps 7.7%
Envista Q2 Revenue Jumps 7.7%
Envista Q2 Revenue Jumps 7.7%
Positive
Zacks Investment Research
3 weeks ago
New Strong Buy Stocks for August 5th
ARMN, QUAD, NVST, INDV and BJRI have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2025.
New Strong Buy Stocks for August 5th
Neutral
Seeking Alpha
3 weeks ago
Envista: Still Hold Rated, Near-Term Uncertainties Weighing On The Outlook
Envista's Q2 results showed broad-based growth, segment recovery, and improved margins, signaling early signs of stabilization and operational turnaround. Spark and implants businesses are rebounding, with Spark on track for profitability and cost efficiencies, and implants seeing sustained growth across regions. One-time revenue tailwinds, FX and tariff risks, and ongoing China uncertainty temper the near-term outlook and earnings growth potential.
Envista: Still Hold Rated, Near-Term Uncertainties Weighing On The Outlook
Charts implemented using Lightweight Charts™